Top Stories
Preliminary Phase III data from the ADEPT programme presented at CTAD come as the company awaits pivotal readouts next year.
The biotech's lead asset is a bispecific antibody currently in Phase I testing for solid tumours and haematologic cancers.
The decision follows scrutiny over her positions on vaccines, mifepristone and other health policy issues.
The decision follows a three-month review extension and a $300-million financing round by maker Beren Therapeutics.
The move to scrap nemtabrutinib follows a review of the Phase III BELLWAVE-011 trial suggesting its benefits may not outweigh the risks.
Conference News
NEWPORT BEACH, CA, UNITED STATES, November 18, 2026 /EINPresswire.com/ -- Regeneration Biomedical, Inc., a clinical-stage biotechnology company developing regenerative therapies for neurodegenerative ...
Immuto’s structural surfaceomics platform reveals a distinct structural landscape on patient-derived KRAS-mutant colorectal cancer models compared to healthy colon organoidsCAMBRIDGE, Mass.--(BUSINESS...
IAM-C1, a selective dual CDK2/4 inhibitor, showed single-agent antitumor activity across CDK2-, CDK4- and CDK2/CDK4-dependent models, including a CDK4/6 inhibitor-resistant breast cancer patient-deriv...
Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol cont...
Pan-tumor potential with responses across six dose levels and five of eight tumor types (EGFRm NSCLC, UC, CRC, SCCHN, NSCLC-WT)63% ORR in a pretreated EGFRm NSCLC population, the majority of whom were...



